国药集团一致药业股份有限公司 第十届董事会2025年第七次临时会议决议公告

Group 1 - The company held its seventh temporary board meeting on November 27, 2025, with all nine directors present, confirming compliance with legal and regulatory requirements [2] - The board approved the "Valuation Enhancement Plan" with a unanimous vote of 9 in favor [3] - The board also approved the revision of the "Strategic Committee Work System" and the establishment of an "ESG Management Method" [5][7] Group 2 - The company has developed a valuation enhancement plan in response to regulatory requirements due to its stock price being below the net asset value per share for 12 consecutive months [28][29] - The plan focuses on strengthening core business, improving governance, enhancing shareholder returns, and ensuring high-quality information disclosure [30][31][32][34] - The company aims to maintain a cash distribution of at least 20% of the annual distributable profits over the next three years, with a total cash distribution not less than 60% of the average annual distributable profits from the last three years [32][33] Group 3 - The company announced the resignation of Vice President Chen Changbing due to work adjustments, effective immediately upon delivery of the resignation report [42] - Chen will continue to hold other positions within the company, and his resignation will not affect normal operations [42] - The company expressed gratitude for Chen's contributions during his tenure [43]

国药集团一致药业股份有限公司 第十届董事会2025年第七次临时会议决议公告 - Reportify